<DOC>
	<DOCNO>NCT02282605</DOCNO>
	<brief_summary>Study determine efficacy , safety tolerability two concentration XF-73 nasal gel combination body face wash chlorhexidine gluconate cloth eradicate nasal carriage Staphylococcus aureus .</brief_summary>
	<brief_title>Study Nasal Decolonisation Staphylococcus Aureus ( SA ) Safety Tolerability XF-73 Nasal Gel Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<criteria>1 . Normal , healthy male female subject age 18 75 year . 2 . Subjects confirm persistent nasal SA carrier , define 3 separate , SA positive culture nasal swab . Two positive culture obtain screen visit 12 week prior inclusion least two week apart . The final confirmatory culture obtain nasal swab day admission unit ( day 1 ) . Note : Dosing XF73 may commence result day 1 swab obtain . If result negative , subject withdrawn . 3 . Subjects able willing provide write informed consent participate study 4 . Subjects body mass index ( BMI ) ≥18.5 kg/m2 ≤ 32kg/m2 . 5 . Subjects agree take part another clinical trial time study period . 1 . Female subject may pregnant lactate . 2 . Subjects acute chronic illness infection . 3 . Subjects smoke within 3 month prior screen . 4 . Subjects females childbearing potential , define physiologically capable become pregnant , UNLESS use one follow acceptable method contraception ; establish use oral , injected implant hormonal contraception , intrauterine Device ( IUD Coil AND barrier Method ( condom diaphragm cervical/vault cap ) plus spermicidal cream/gel . Contraceptive use continue throughout study 1 month follow completion study . 5 . Subjects fertile male , define male physiologically capable conceive offspring , UNLESS subject agree comply acceptable contraception e.g . condom plus spermicidal cream/gel . Contraceptive use continue throughout study 3 month follow completion study . 6 . Subject open wound , lesion , inflammation , erythema infection affect nostril , nose , upper lip area skin close nose . This include herpes simplex lesion discoid lupus . 7 . Subjects currently symptomatic upper respiratory tract infection , nasopharyngitis , influenza condition involve increase nasal secretion seasonal chronic , allergic rhinitis . 8 . Subjects history drug alcohol abuse previous 12 month positive urine drug test substance abuse . 9 . Subjects know clinically significant history atopy hypersensitivity drug latex . 10 . Subjects history serious illness , cancer psychiatric condition . 11 . Subjects know skin photosensitivity . 12 . Subjects personal family history porphyria . 13 . Subjects treat take prescribed overthecounter medication within 14 day prior admission , exception hormonal contraceptive hormone replacement therapy . 14 . Subjects take used topical systemic antibiotic within month prior screen . 15 . Subjects know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody , positive result test human immunodeficiency virus ( HIV ) antibodies 16 . Subjects participate clinical trial within last 3 month . 17 . Subjects expose XF73 part previous clinical trial . 18 . Subjects clinically significant abnormality vital sign laboratory analyse screen baseline , base opinion investigator . 19 . Subjects nasal polyp significant anatomical nasal abnormality . 20 . Subjects history nasal surgery , include cauterization last 12 month . 21 . Subjects history multiple episode [ &gt; 3 ] epistaxis within last 12 month . 22 . Subjects know dermal sensitivity benzalkonium chloride quaternary ammonium disinfectant . 23 . Subjects insitu nasal jewellery open nasal piercings . 24 . Subjects know dermal sensitivity chlorhexidine gluconate ( CHG ) . 25 . Subjects history abnormal bleeding , bruising , frequent nosebleed diagnosis von Willebrand disease . 26 . Subjects autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>